Antigen production and development of an indirect ELISA based on the nucleocapsid protein to detect human SARS-CoV-2 seroconversion.


Journal

Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
ISSN: 1678-4405
Titre abrégé: Braz J Microbiol
Pays: Brazil
ID NLM: 101095924

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 15 03 2021
accepted: 21 06 2021
pubmed: 4 8 2021
medline: 25 11 2021
entrez: 3 8 2021
Statut: ppublish

Résumé

Serological assays are important tools to identify previous exposure to SARS-CoV-2, helping to track COVID-19 cases and determine the level of humoral response to SARS-CoV-2 infections and/or immunization to future vaccines. Here, the SARS-CoV-2 nucleocapsid protein was expressed in Escherichia coli and purified to homogeneity and high yield using a single chromatography step. The purified SARS-CoV-2 nucleocapsid protein was used to develop an indirect enzyme-linked immunosorbent assay for the identification of human SARS-CoV-2 seroconverts. The assay sensitivity and specificity were determined analyzing sera from 140 RT-qPCR-confirmed COVID-19 cases and 210 pre-pandemic controls. The assay operated with 90% sensitivity and 98% specificity; identical accuracies were obtained in head-to-head comparison with a commercial ELISA kit. Antigen-coated plates were stable for up to 3 months at 4 °C. The ELISA method described is ready for mass production and will be an additional tool to track COVID-19 cases.

Identifiants

pubmed: 34342836
doi: 10.1007/s42770-021-00556-6
pii: 10.1007/s42770-021-00556-6
pmc: PMC8329412
doi:

Substances chimiques

Antibodies, Viral 0
Coronavirus Nucleocapsid Proteins 0
Nucleocapsid Proteins 0
Phosphoproteins 0
nucleocapsid phosphoprotein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2069-2073

Informations de copyright

© 2021. Sociedade Brasileira de Microbiologia.

Références

Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. https://doi.org/10.1056/NEJMoa2001017
doi: 10.1056/NEJMoa2001017 pubmed: 32877576 pmcid: 7494251
Petherick A (2020) Developing antibody tests for SARS-CoV-2. Lancet. https://doi.org/10.1016/s0140-6736(20)30788-1
doi: 10.1016/s0140-6736(20)30788-1 pubmed: 32247384 pmcid: 7270070
Cheng VCC, Lau SKP, Woo PCY, Kwok YY (2007) Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. https://doi.org/10.1128/CMR.00023-07
doi: 10.1128/CMR.00023-07 pubmed: 17934078 pmcid: 2176051
den Hartog G, Schepp RM, Kuijer M et al (2020) SARS-CoV-2–specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis. https://doi.org/10.1093/infdis/jiaa479
doi: 10.1093/infdis/jiaa479
Huergo LF, Conzentino MS, Gerhardt ECM et al (2020) Magnetic bead-based ELISA allow inexpensive, rapid and quantitative detection of human antibodies against SARS-CoV-2. medRxiv. https://doi.org/10.1101/2020.07.26.20162255
doi: 10.1101/2020.07.26.20162255
Huergo LF, Selim KA, Conzentino MS et al (2021) Magnetic bead-based immunoassay allows rapid, inexpensive, and quantitative detection of human SARS-CoV-2 antibodies. ACS Sensors 0(0).  https://doi.org/10.1021/acssensors.0c02544
Cai X, Chen J, Li Hu J et al (2020) A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019. J Infect Dis. https://doi.org/10.1093/infdis/jiaa243
doi: 10.1093/infdis/jiaa243 pubmed: 32563187
Rikhtegaran Tehrani Z, Saadat S, Saleh E et al (2020) Specificity and performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays. medRxiv. https://doi.org/10.1101/2020.08.05.20168476
Long QX, Tang XJ, Shi QL et al (2020) Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. https://doi.org/10.1038/s41591-020-0965-6
doi: 10.1038/s41591-020-0965-6 pubmed: 33020648 pmcid: 7446729

Auteurs

Marcelo S Conzentino (MS)

Setor Litoral, UFPR, Matinhos, Paraná, Brazil.

Karl Forchhammer (K)

Interfakultäres Institut Für Mikrobiologie Und Infektionsmedizin der Eberhard-Karls Universität Tübingen, Tübingen, Germany.

Emanuel M Souza (EM)

Biochemistry and Molecular Biology Department, UFPR, Curitiba, Paraná, Brazil.

Fábio O Pedrosa (FO)

Biochemistry and Molecular Biology Department, UFPR, Curitiba, Paraná, Brazil.

Meri B Nogueira (MB)

Complexo Hospital das Clínicas, UFPR, Curitiba, Paraná, Brazil.

Sônia M Raboni (SM)

Complexo Hospital das Clínicas, UFPR, Curitiba, Paraná, Brazil.

Fabiane G M Rego (FGM)

Post-Graduation Program in Pharmaceutical Sciences, UFPR, Curitiba, Paraná, Brazil.

Dalila L Zanette (DL)

Instituto Carlos Chagas - FioCruz, Curitiba, Paraná, Brazil.

Mateus N Aoki (MN)

Instituto Carlos Chagas - FioCruz, Curitiba, Paraná, Brazil.

Jeanine M Nardin (JM)

Hospital Erasto Gaertner, Curitiba, Paraná, Brazil.

Bruna Fornazari (B)

Hospital Erasto Gaertner, Curitiba, Paraná, Brazil.

Hugo M P Morales (HMP)

Hospital Erasto Gaertner, Curitiba, Paraná, Brazil.

Paola A F Celedon (PAF)

Instituto de Biologia Molecular Do Paraná, IBMP, Curitiba, Paraná, Brazil.

Carla V P Lima (CVP)

Instituto de Biologia Molecular Do Paraná, IBMP, Curitiba, Paraná, Brazil.

Sibelle B Mattar (SB)

Instituto de Biologia Molecular Do Paraná, IBMP, Curitiba, Paraná, Brazil.

Vanessa H Lin (VH)

Instituto de Biologia Molecular Do Paraná, IBMP, Curitiba, Paraná, Brazil.

Luis G Morello (LG)

Instituto Carlos Chagas - FioCruz, Curitiba, Paraná, Brazil.
Instituto de Biologia Molecular Do Paraná, IBMP, Curitiba, Paraná, Brazil.

Fabricio K Marchini (FK)

Instituto Carlos Chagas - FioCruz, Curitiba, Paraná, Brazil.
Instituto de Biologia Molecular Do Paraná, IBMP, Curitiba, Paraná, Brazil.

Rodrigo A Reis (RA)

Setor Litoral, UFPR, Matinhos, Paraná, Brazil.

Luciano F Huergo (LF)

Setor Litoral, UFPR, Matinhos, Paraná, Brazil. luciano.huergo@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH